Dalton Venture

Dalton Venture (道彤投资) is a Chinese early-stage venture fund focused on healthcare — medical devices, innovative medical technology, and increasingly biomanufacturing and brain-computer interfaces. The firm is led by founding managing partner Sun Qi, with Huang Ning as founding partner and Lin Zhengcheng as managing director; deep post-investment management is described as one of its signature traits . Its deal pace is best illustrated by 2023, when it backed eight healthcare companies — including MacroLux, ICE Intelligent Healthcare, Fuyi Medical and MolBreeding — spanning neuro-intervention, endoscopy, surgical robotics and seed technology . More recently it has pushed into frontier areas: it is an early backer of Gestalt Technology, an ultrasound-based brain-computer interface company whose latest round set a domestic funding record for the sector (as of mid-2026) , and in October 2025 it co-launched Shanghai's first biomanufacturing industry fund with OPM Biosciences . The firm has picked up steady industry recognition along the way, including spots on Zero2IPO's 2025 top-30 early-stage and healthcare investor lists and a Touzhong "best early-stage VC top 20" ranking .